Neuberger Berman Group
ADMA icon

Neuberger Berman Group’s ADMA Biologics ADMA Stock Holding History

Neuberger Berman Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
19,231
+6,294
+49% +$57.4K ﹤0.01% 2203
2026
Q1 		$117K Sell
12,937
-368,848
-97% -$5.82M ﹤0.01% 2058
2025
Q4 		$6.96M Sell
381,785
-131,479
-26% -$2.22M 0.01% 896
2025
Q3 		$7.52M Buy
513,264
+86,239
+20% +$1.48M 0.01% 867
2025
Q2 		$7.78M Buy
427,025
+413,847
+3,140% +$8.44M 0.01% 850
2025
Q1 		$261K Buy
+13,178
New +$228K ﹤0.01% 1740
2024
Q3 		– Sell
-12,247
Closed -$137K – 1928
2024
Q2 		$137K Buy
+12,247
New +$103K ﹤0.01% 1791

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Neuberger Berman Group's ADMA Position: Q2 2026 in Review

Neuberger Berman Group increased its ADMA Biologics (ADMA) stake by 49% in Q2 2026, buying an estimated $57.4K and bringing the position to 19,231 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #2203.

Neuberger Berman Group first reported a position in ADMA in Q2 2024 and has held it in 7 quarters since. The position peaked at $7.78M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Neuberger Berman Group held 19,231 shares of ADMA Biologics worth $161K as of Q2 2026.
  • Neuberger Berman Group bought 6,294 ADMA Biologics shares in Q2 2026, an estimated $57.4K.
  • ADMA Biologics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2203 holding.
  • Neuberger Berman Group first reported a position in ADMA Biologics in Q2 2024 and has held it in 7 quarters since.
  • Neuberger Berman Group's ADMA Biologics position peaked at $7.78M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.